Recent studies indicate that GLP1 medications significantly reduce opioid overdoses and alcohol intoxication rates among individuals with substance use disorders. As the alcohol industry faces declining sales, driven largely by a small percentage of heavy drinkers, the potential impact of these medications could lead to a drastic restructuring of the market. If the trend continues, the loss of a key consumer base may result in substantial layoffs and a major industry meltdown.
